Table 2.
Characteristics of the subgroup of patients with post-vaccination serology testing
| All patients with hematologic malignancy | Lymphoma patients | Myeloma patients | |
|---|---|---|---|
| (n = 54) | (n = 33) | (n = 20) | |
| Age (years) | 68.8(61.2–76.8) | 66.6(52.3–76.4) | 70.7 (63.5–77.0) |
| Male | 32 (59.3%) | 19 (57.6%) | 12 (60.0%) |
|
PET-1 patients Days from Vac-1 to PET-CT Days from PET-CT to Serology |
16 (29.6%) 11 (7–15.75) 29.5 (21–34.5) |
8 (24.2%) 10 (4–14.75) 32 (21–37.25) |
7 (35.0%) 14 (10–17) 26 (21–31) |
|
PET-2 patients Days from Vac-2 to PET-CT Days from PET-CT to Serology |
38 (70.4%) 17 (10–31) 0.5 (−12–8) |
25 (75.8%) 14 (9–28) 1 (−9.5–9.5) |
13 (65.0%) 25 (11.5–32.5) −4 (−13.5–5) |
| Days from Vac-2 to serology | 17 (14.75–21) | 17 (15–21.5) | 16.5 (14.25–21) |
|
Staging Monitor response to therapy Recurrence Follow-up with NED |
7 (13.0%) 35 (64.8%) 3 (5.6%) 9 (16.7%) |
3 (9.1%) 21 (63.6%) 2 (6.1%) 7 (21.2%) |
4 (20.0%) 13 (65.0%) 1 (5.0%) 2 (10.0%) |
Categorical variables are reported as frequency and percentage; Continuous variables are reported as median and IQR. Vac-1, first vaccine dose; Vac-2, booster vaccine dose; NED, no evidence of disease